Champignon

Champignon Brands, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm

Retrieved on: 
Friday, May 14, 2021
Musicians, Beatboxers, Champignon

Sufficient internal controls over financials were not maintained by Champignon.

Key Points: 
  • Sufficient internal controls over financials were not maintained by Champignon.
  • Champignon issued financial statements that were false and could not be relied upon, requiring restatement.
  • Champignon engaged in acquisitions with undisclosed third parties, and as a result, the British Columbia Securities Commission would suspend Champignon from trading.
  • Investors suffered damages when the market learned the truth about Champignon.\nA class action lawsuit has already been filed.

Dr. Roger McIntyre Announces Changes to the Board of Champignon Brands Inc.

Retrieved on: 
Thursday, February 4, 2021
Musicians, Beatboxers, Champignon

VANCOUVER, BC, Feb. 4, 2021 /PRNewswire/ - February 4, 2021 - Dr. Roger McIntyre, Chairman of the Board of Directors of Champignon Brands Inc. today announces changes to the Champignon Board of Directors ("Champignon" or the "Company") (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF).

Key Points: 
  • VANCOUVER, BC, Feb. 4, 2021 /PRNewswire/ - February 4, 2021 - Dr. Roger McIntyre, Chairman of the Board of Directors of Champignon Brands Inc. today announces changes to the Champignon Board of Directors ("Champignon" or the "Company") (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF).
  • D. (Hon), appointed to the Board of Directors of Champignon on May 22, 2020, and elected Vice-Chair of the Board on September 14, 2020, after completing his six-month commitment to Champignon, has retired from the Board.
  • "We thank Dr. Wilkerson for the guidance and the expertise that he brought to Champignon," said Dr. Roger McIntyre.
  • "His sage counsel has served us well and we appreciate his dedication and active participation in preparing Champignon for its successful future."

Champignon Brands Announces New CFO and New General Counsel

Retrieved on: 
Monday, January 11, 2021
Drugs, Psychoactive drugs, Musicians, Amines, Chloroarenes, Dissociative drugs, Nicotinic antagonists, Sedatives, Champignon, Brand, Health care, Ketamine

These appointments complete the Company's new top management team put into place by Dr. McIntyre and the Champignon Board of Directors.

Key Points: 
  • These appointments complete the Company's new top management team put into place by Dr. McIntyre and the Champignon Board of Directors.
  • Champignon Brands Inc. ( https://champignonbrands.com ) is a research-driven company specializing in breakthrough ketamine treatment for depression and other mental health conditions.
  • Do not rely on communication through the Champignon Brands website of the emails/telephone numbers above for urgent medical needs.
  • Champignon Brands Inc. does not provide medical advice.If you have any specific medical questions or are seeking advice, please consult with your health care provider.

Champignon Brands Updates Investors on Changes at the Top

Retrieved on: 
Tuesday, November 24, 2020
Drugs, Psychoactive drugs, Musicians, Amines, Chloroarenes, Dissociative drugs, Nicotinic antagonists, Sedatives, Ketamine, Tassili Airlines, Champignon

The Company intends to expand its board with additional outside directors to be drawn from business and science.

Key Points: 
  • The Company intends to expand its board with additional outside directors to be drawn from business and science.
  • The Company has re-designed its website to facilitate proper access to current information by investors and the wider public.
  • Champignon Brands Inc. ( https://champignonbrands.com ) is a research-driven Company specializing in breakthrough ketamine treatment for depression, and other mental health conditions and its suicidal implications as well as delivery platforms for other health products.
  • The Company works closely with subsidiaries that include AltMed Capital Corp. ("AltMed"), Novo Formulations Ltd., Artisan Growers Ltd., and Tassili Life Sciences Corp.

REPEAT - Champignon Identifies Synthetic Ketamine and Psilocybin/Psilicin Metabolite Targets; Selects Dalriada to Advance NCE IP Portfolio

Retrieved on: 
Monday, June 8, 2020
Musicians, Singers, Entertainers, Beatboxers, Champignon

The Company anticipates that through this partnership, a robust pipeline of preclinical and clinical assets with strong IP protection will be delivered.

Key Points: 
  • The Company anticipates that through this partnership, a robust pipeline of preclinical and clinical assets with strong IP protection will be delivered.
  • It is with great pleasurethat we welcome the Dalriada group to Champignon,commented Dr Joseph Gabriele, Special Advisor, Champignon.
  • Champignon has developed a comprehensive working arrangement with Dalriada focusing on R&D.
  • Dalriada is aligned with Champignon with respect to quality, efficiency, and their results-oriented approach, stated Dr. McIntyre, CEO of Champignon.

Champignon Identifies Synthetic Ketamine and Psilocybin/Psilicin Metabolite Targets; Selects Dalriada to Advance NCE IP Portfolio

Retrieved on: 
Monday, June 8, 2020
Musicians, Singers, Entertainers, Beatboxers, Champignon

The Company anticipates that through this partnership, a robust pipeline of preclinical and clinical assets with strong IP protection will be delivered.

Key Points: 
  • The Company anticipates that through this partnership, a robust pipeline of preclinical and clinical assets with strong IP protection will be delivered.
  • It is with great pleasurethat we welcome the Dalriada group to Champignon,commented Dr Joseph Gabriele, Special Advisor, Champignon.
  • Champignon has developed a comprehensive working arrangement with Dalriada focusing on R&D.
  • Dalriada is aligned with Champignon with respect to quality, efficiency, and their results-oriented approach, stated Dr. McIntyre, CEO of Champignon.

Champignon Expands to U.S., To Acquire California Based Ketamine Centre – Wellness Clinic of Orange County

Retrieved on: 
Tuesday, May 12, 2020
Psychoactive drugs, Drugs, Neurochemistry, Antidepressants, Amines, Chloroarenes, Nicotinic antagonists, Sedatives, Ketamine, Infusion therapy, Champignon

The Wellness Clinic owns and operates a state-of-the-art ketamine infusion treatment center located within the Mission Hospitals Laguna Beach campus.

Key Points: 
  • The Wellness Clinic owns and operates a state-of-the-art ketamine infusion treatment center located within the Mission Hospitals Laguna Beach campus.
  • This cutting-edge clinic is an authority in ketamine infusion therapy and is actively involved in research and complementary treatment protocols.
  • We are thrilled to begin executing on our North American expansion strategy by acquiring our first U.S. based, revenue generating ketamine centre- Wellness Clinic of Orange County, said Dr. Roger McIntyre, Chief Executive Officer, Champignon.
  • Champignon continues to be inspired by sustainability, as its medicinal mushroom-infused SKUs are organic, non-GMO and vegan certified.

REPEAT - Champignon Appoints Dr. Roger McIntyre as Chief Executive Officer

Retrieved on: 
Monday, May 11, 2020
Musicians, Singers, Entertainers, Edible fungi, Beatboxers, Champignon, Birdsall, Skus, Agaricus bisporus

My overarching aim as Chief Executive Officer is to establish Champignon as the apotheosis of integrated ketamine treatment delivery and the commercialization of our own IP psychedelic-based treatments.

Key Points: 
  • My overarching aim as Chief Executive Officer is to establish Champignon as the apotheosis of integrated ketamine treatment delivery and the commercialization of our own IP psychedelic-based treatments.
  • We are extremely pleased and fortunate to be able to bring Dr. McIntyre aboard as CEO, commented Gareth Birdsall director of Champignon.
  • The Company also announces that Gareth Birdsall has relinquished the role of CEO to Dr. McIntyre and will maintain his directorship of Champignon.
  • Champignon continues to be inspired by sustainability, as its medicinal mushroom-infused SKUs are organic, non-GMO and vegan certified.

Champignon Appoints Dr. Roger McIntyre as Chief Executive Officer

Retrieved on: 
Monday, May 11, 2020
Psychoactive drugs, Drugs, Neurochemistry, Amines, Ketamine, RTT, OTC Markets Group, Society for Human Resource Management, Champignon, Birdsall

VANCOUVER, British Columbia, May 11, 2020 (GLOBE NEWSWIRE) -- Champignon Brands Inc. (Champignon or the Company) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), a human optimization sciences Company with an emphasis on ketamine and psychedelic medicine, is pleased to announce that it has appointed Dr. Roger McIntyre as Chief Executive Officer.

Key Points: 
  • VANCOUVER, British Columbia, May 11, 2020 (GLOBE NEWSWIRE) -- Champignon Brands Inc. (Champignon or the Company) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), a human optimization sciences Company with an emphasis on ketamine and psychedelic medicine, is pleased to announce that it has appointed Dr. Roger McIntyre as Chief Executive Officer.
  • My overarching aim as Chief Executive Officer is to establish Champignon as the apotheosis of integrated ketamine treatment delivery and the commercialization of our own IP psychedelic-based treatments.
  • We are extremely pleased and fortunate to be able to bring Dr. McIntyre aboard as CEO, commented Gareth Birdsall director of Champignon.
  • The Company also announces that Gareth Birdsall has relinquished the role of CEO to Dr. McIntyre and will maintain his directorship of Champignon.

REPEAT - Champignon Appoints Pat McCutcheon to Board of Directors

Retrieved on: 
Wednesday, May 6, 2020
Musicians, Singers, Entertainers, Edible fungi, Beatboxers, Champignon, McCutcheon, Agaricus bisporus

Mr. McCutcheon is currently Chief Executive Officer of one of the leading global cannabis companies, MediPharm Labs Corp. (MediPharm) (TSX: LABS).

Key Points: 
  • Mr. McCutcheon is currently Chief Executive Officer of one of the leading global cannabis companies, MediPharm Labs Corp. (MediPharm) (TSX: LABS).
  • We are tremendously pleased to have Pat join the Champignon Board, commented Gareth Birdsall, director of Champignon.
  • I am excited to join the Board of Directors of Champignon given its leadership position with the only licensed operating ketamine clinic and integrated research centre of its kind in Canada, stated Pat McCutcheon.
  • Champignon continues to be inspired by sustainability, as its medicinal mushroom-infused SKUs are organic, non-GMO and vegan certified.